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Introduction
Chronic venous insufficiency of the lower extremity is a common vascular disorder. In a general adult population, only 10% of individuals have no clinical signs of venous disease [1] . Prevalence of superficial vein reflux in the Bonn vein study was 21% in an adult population, which increased with age in a linear way [2] . Although all components of the superficial and deep venous system can be affected, the most predominant site of reflux in these patients is the great saphenous vein (GSV). Chronic venous insufficiency has a considerable negative impact on generic and disease-specific quality of life [3] , which is comparable with other chronic disorders [4] . Due to the high prevalence, treatment of patients with varicose veins has a substantial financial burden on health care resources. For many years, the traditional treatment for saphenous vein insufficiency has been high ligation with or without stripping of the GSV for GSV insufficiency and ligation of the saphenopopliteal junction in small saphenous vein (SSV) insufficiency [5] . Long stripping of the GSV was replaced for a "short strip," to reduce the risk of saphenous nerve damage [6] . Surgery is usually performed under general or epidural anesthesia and is an effective method to eliminate reflux in the short term. However, recurrent reflux at the groin is a frequent problem, with an incidence up to 60% after a mean follow-up of 34 years [7] .
Development of minimally invasive procedures was driven by the aim to reduce surgical trauma and to improve longterm success. Today, endovenous techniques, such as endovenous laser ablation (EVLA), radiofrequency ablation (RFA), and ultrasound-guided foam sclerotherapy (UGFS) are common procedures in daily practice. Supposed advantages over traditional surgery include the omission of general and epidural anesthesia, minimal scars, fewer complications [8] , less post-procedural pain [9] [10] [11] , and faster recovery times [12, 13] . Lower recurrence might be the result of decreased neovascularization in the groin and along the stripped saphenous vein segment [14] . However, recent metaanalysis report similar long-term results with traditional surgery and endovenous procedures [15, 16] .
The revolution of different endovenous therapies makes it hard for clinicians to recommend an optimal technique for their patients. This review aims to inform clinicians about outcomes and complications of all endovenous treatment modalities for insufficient varicose veins and describe the various techniques.
2.
Endovenous laser ablation
Technique
EVLA can be performed in an outpatient setting with local tumescent anesthesia. Oral sedatives, such as diazepam, are also used occasionally. Patients are placed in an antiTrendelenburg position to enhance venous pressure and to widen the GSV. The GSV is visualized with duplex ultrasound and a location for cannulation of the vein is selected. Usually a diameter of 43 mm makes the vein suitable for venous access. Normally, the GSV is larger and straighter above than below the knee, which favors this location for most clinicians. In addition, the saphenous nerve is more adjacent to the GSV below the knee, increasing the risk of saphenous nerve injury. Venous access is obtained by a micropuncture needle (16À18Fr) under ultrasound guidance. A guide wire is advanced through the hollow needle into the GSV and positioned at the level of the saphenofemoral junction (SFJ). The standard guide wire is J-tipped and can be advanced easily. However, severe tortuosity, small diameter of the vein, thrombotic remnants, or large side branches can harden the advancement of the guide wire. In this case, caution is necessary, and proceeding increases the risk of perforation and embolic complications. The use of different-shaped guide wires can be helpful in these situations. After the guide wire has been placed at the level of the SFJ, and a small cutaneous incision is made, a guiding sheath is advanced over the guide wire. The guiding sheath is marked every centimeter to determine the exact length of segment to be treated. Subsequently, the laser fiber can be introduced after removal of the guide wire. Positioning of the sheath and laser fiber with duplex ultrasound 15 to 20 mm below the SFJ is the most essential step of the procedure. Three landmarks for proper positioning are the superficial epigastric vein, the circumflex artery between the femoral vein and the GSV, and the valve at the SFJ.
Tumescence anesthesia is infiltrated along the entire course of the GSV, starting at the cannulation site. Under direct ultrasound guidance, tumescence solution should be injected between the perivenous fascia, so the vein will collapse through the circumferential surrounding of the solution. The maximum recommended dose of lidocaine with epinephrine (1:100,000) is 7 mg/kg, with a maximum amount of 500 mg. Most tumescence solutions are diluted in 500 mL saline 0.9% or Ringer's lactate. The amount of tumescence anesthesia depends on the length of the vein to be treated. Tumescence anesthesia provides a cooling area to minimize thermal injury on the surrounding tissue. In addition, it induces vasospasm to maximize the effect of heat on the vascular wall.
The laser fiber is connected to the generator. After activation, the sheath and laser fiber are simultaneously withdrawn with a speed depending on the power and wavelengths of the generator. Compression stockings are usually administered for 1 to 2 weeks after the procedure.
Relative contraindications for EVLA are thrombus in the target vein, an inability to ambulate, severe arterial disease, deep vein thrombosis, pregnancy, and patients who are breastfeeding.
2.2.
Mechanism of action EVLA uses electromagnetic radiation (light) through a process of optimal amplification to obliterate the vein [17] . The laser energy is absorbed by blood in the vein and converted to heat. As a result, steam bubbles are produced at the tip of the laser fiber, which distribute along the entire inner vascular wall and provide homogeneous thermal injury to the endothelium [18, 19] . Steam bubble formation is a local and reversible process that, after collapse of the bubble, causes no risk of air embolism to the patient. The volume of the lasergenerated steam bubbles is directly correlated to the amount of laser energy. In histologic studies of vein specimens, a completely damaged intima was found immediately after EVLA [20, 21] . Most of the laser-induced injury in the media does not reach deeper than the inner one-third of the entire vein wall [21] . However, carbonization and perforation are observed, presumably where the tip of the laser has direct contact with the vein wall. Histologic samples taken from the GSV showed absence of endothelium, deposits of fibrin in the vascular lumen, and thrombus organization with evidence of muscle wall damage, 3 months after EVLA [22] .
Lasers with wavelengths from 808 to 1,560 nm have been used for EVLA. Wavelength is a determinant of laser penetration and absorption by blood. A longer wavelength results in lower energy absorption and possibly fewer vein perforations. Although several studies analyzed the effect of different wavelengths on the occlusion rate of EVLA, most of the lasers appeared to have similar results [23, 24] . In addition, a recently developed covered-tip design (jacket-tip, gold-tip, tulip-tip, ball-tip, radial) employs a cover at the distal tip of the laser fiber (Fig. 1) . This cover prevents the unrevealed bare tip to have contact with the vein wall, which prevents perforation and subsequently pain and bruising. Several studies observed a decrease in postprocedural pain with the use of covered tips, although a higher failure rate was seen with covered tips [25, 26] . The total amount of energy delivered is expressed as J/cm and reveals the product of power (W) and the withdrawal velocity of the laser fiber (cm/s). A range of 60 to 80 J/cm is usually accepted, administered in either a pulsed or continuous mode. Higher doses of laser energy have shown to be more effective in venous obliteration, although more side effects can occur [27] [28] [29] .
2.3.

Outcome
In 2001, Navarro et al [30] and Min et al [31] were the first to describe a large series of EVLA [30, 31] . Both studies, with 40 and 90 patients, respectively, showed a 100% and 96% occlusion rate of the treated GSV without significant complications. Several prospective studies have been published subsequently to determine the outcomes of EVLA in treatment of varicose veins. The reported occlusion rates are listed in Table 1 and vary between 62% and 100% [9, 12, 13, 23, 26, . Although occlusion rates 490% are mostly reported in large series, results seems to decrease with time. A recent prospective study with 1,020 limbs observed failure rates with duplex ultrasound of 7.7% at 1 year and 13.1% at 2 and 3 years [108] . In a randomized controlled trial of EVLA with or without high saphenous ligation, occlusion rates at 5 years followup were 98% and 88% , respectively [86] . The difference between these groups was not significant. Another large study including 449 veins reported a 93% occlusion rate after 3 years [32] . A meta-analysis shows that results of EVLA are significantly more effective than RFA, surgery, and UGFS [16] .
Complications
Deep venous thrombosis is considered a major complication of endothermal treatment, with a reported incidence of 0% to 5.7% [109] . To reduce the risk of thrombosis, proper positioning of the laser tip, with a general distance of 1.5 to 2 cm below the SFJ, is essential. However, extension of the thrombus of the GSV into the common femoral vein has been reported [110] . This phenomenon is called endothermal heatinduced thrombosis. Pre-existent thrombophilic disorders and the use of general anesthesia, which does not allow direct mobilization after the treatment, are suggested as potential risk factors for thrombus extension to develop [109] . Some practitioners recommend routine use of low-molecularweight heparin after EVLA. Pulmonary embolism has only been described in a few reports, although a direct correlation with deep venous thrombosis was not observed [111] . The most common side effects of EVLA are pain and bruising, which occur in almost all patients [109] . High temperatures of laser energy, which causes small perforations in the vein, are hypothesized to support this effect. Postprocedural pain usually revolves within 2 weeks after treatment. The use of covered-tip lasers or lower laser energy is associated with reduced postprocedural pain after EVLA [25, 26] . Comparative studies with EVLA and RFA showed significantly less postprocedural pain with the RFA method [106, 112] . Also, an unpleasant burning smell and taste are often mentioned by patients treated with EVLA [113] . Skin burns have been reported in the early experiences of EVLA, but might be a consequence of inadequate tumescence anesthesia [26, 108, 114] . Attention should be paid to situations in which the insufficient GSV extends into a major side branch outside the fascia and is situated very superficially. Other seldom reported complications specific for EVLA are hyperpigmentation, superficial thrombophlebitis, arteriovenous fistula, and paresthesia [111, [115] [116] [117] . An exceptional complication is the remnant of used material in the vasculature [118] .
3.
Radiofrequency ablation
Technique
RFA can also be performed in an outpatient setting with local tumescence anesthesia. Preparations and introduction are similar to EVLA, with the exception that only a short sheath is used, as the catheter can be advanced without a sheath. contact with the vein wall by creating vasospasm. It also provides a protective area for thermal injury. The RFA catheter is then connected to a radiofrequency generator. A thermocouple on the catheter monitors the temperature of the endothelium, and is able to maintain temperature at a certain level through a feedback system at the generator [119] . Temperature is normally maintained at 851 to 901C during withdrawal. The catheter is continuously pulled back at about 3 cm/min, but can be increased with higher temperature settings [119] . Compression stockings are usually indicated for 1 to 2 weeks after the procedure. In 2006, the Covidien ClosureFast TM (Covidien, Mansfield, MA) catheter, formerly known as VNUS ClosureFast TM , was introduced. This catheter uses segmental ablation in contrast with a continuous pullback. A heating element at the distal end of the catheter allows vein segments of 7 cm to be obliterated in energy cycles of 20 seconds (Fig. 2) . The temperature is maintained at 1201C during an energy cycle. When the catheter is placed 2 cm below the SFJ, tumescent anesthesia is applied with a recommended volume of 10 mL/ cm of treated vein. This new technology results in faster treatment time, and every 20 seconds the catheter is segmentally withdrawn for 7 cm [120] . Notably, the most proximal part of the GSV is treated with two energy cycles.
Radiofrequency-induced thermotherapy (RFITT) (Celon AG, Medical Instruments, Teltow, Germany) is another technique using radiofrequency energy. The RFITT catheter has a rounded tip and contains an acoustic impedance feedback function, ensuring that the energy output is adapted to the size of the vein wall. The bipolar catheter tip needs to moved constantly with a pullback speed of 0.5 to 1 cm per second, depending on the used power settings of the generator ) are used to generate temperatures of 801 to 1201C. In contrast to EVLA, RFA requires direct contact of the endothelium with the catheter. Therefore, manual compression on the vein from the outside is recommended by some practitioners to enhance contact during treatment. Adequate tumescence anesthesia and emptying of the vein, before treatment, are also possibilities to increase contact of the catheter with the vein.
RFITT uses blood and the surrounding vein wall as a conductor of bipolar energy to generate temperatures up to 601 to 1001C [123] . Therefore, the catheter does not need direct contact with the vein wall.
Radiofrequency energy causes acute thermal damage to the endothelium. The heat-related inflammatory response results in endothelial denudation and swelling of the vein wall. It also induces restructuring and repair processes with collagen remodeling and proliferation of fibroblast, leading to complete occlusion of the vein [124] . In a histologic study with bovine veins, RFA showed induration and thickening of the vein wall and contraction of the vein lumen [125] . No evidence of vein perforation or thermal damage of the surrounding tissue was observed under macroscopic investigation. However, a complete occlusion was not seen in any of the treated veins. All veins showed a microscopically circular disintegration of the intima. Unfortunately, histologic in vivo studies with RFA are not available to date.
Outcome
Several studies have been published on the short-and longterm efficacy of RFA in the treatment of varicose veins. In 2002, Weiss and Weiss reported the first large series in 140 patients with 90% success rate 2 years after treatment [126] . These patients had complete disappearance of the treated GSV. The largest prospective study, including 1,222 limbs treated with VNUS Closure TM , reported vein occlusion rates after 1 and 5 years of 87.1% and 87.2%, respectively [127] . Clinical improvement was seen in 85% of the limbs with anatomical success 5 years after RFA. The reported occlusion rates of prospective series are listed in Table 2 and vary between 67% and 100% [10, 11, 13, 78, 89, 91, 106, 107, [120] [121] [122] 124, . First results of radiofrequency segmental ablation were published by Proebstle et al in 2008 [120] . Occlusion rates were 99.6% obtained from 62 limbs after 6 months. Radiofrequency segmental ablation using the Covidien ClosureFast TM catheter was superior to VNUS Closure TM ,
with occlusion rates of 98% and 88%, respectively, after 1 week [153] . In a randomized controlled study of RFA comparing ligation of the SFJ and surgical stripping, outcomes after 2 years were identical [151] .
Complications
In the early series of treatment with RFA, serious side effects, like paresthesia and skin burns, were reported, but these incidences decreased after induction of tumescent anesthesia with RFA [140] . Rates of paresthesia dropped from 14.5% to 9.1% and rates of skin burn decreased from 1.8% to 0.5%. Most events of paresthesia are transient and resolve spontaneously [127] . Below the knee, the saphenous nerve is located adjacent to the GSV. Therefore, treatment limited to the upper limb can significantly reduce paresthesia [131] . Other possible complications with RFA are comparable to EVLA. Superficial thrombophlebitis, often described as an erythematous area over the treated vein segment, is inherent to endovenous procedures, as obliteration of the GSV requires injury to the vein wall. This self-limiting complication is reported in approximately 5% [161] .
4.
Ultrasound-guided foam sclerotherapy
Technique
UGFS is an endovenous sclerosis technique that is performed in an outpatient setting. Foam is obtained by mixing a sclerosant with gas. Several methods have been described to prepare the foam. The most extensively used method is the Tessari method [162] . Two 5-mL Luerlock syringes are connected by a three-way stopcock. One syringe contains 1 mL of the sclerosant, the other contains 4 mL room air (ratio 1:4) [163] . This mixture is twisted about 10 to 20 times between the two syringes and then it becomes foam. Also, different gases and methods of preparation are described [164] . The prepared foam is stable for about 2 minutes and therefore needs quick injection [165, 166] . For UGFS of insufficient saphenous veins, two different sclerosants can be used, including sotradecol (sodium tetradecyl sulphate) 1% and 3% and polidocanol 1%, 2%, and 3%. The chosen concentration is related to the diameter of the treated vein segment [167] . Venous access is obtained directly under ultrasound guidance with either a butterfly needle or a microcatheter. Because most of the foam moves along with the venous flow, the patient is placed in horizontal or reverse Trendelenburg position to enhance contact between the vein wall and foam. For the treatment of GSV insufficiency, the GSV is punctured around the knee. The foam is injected under continuous monitoring with ultrasound, and continued until the foam reaches the SFJ. Some additional injections can be given to make sure that the insufficient veins and also major tributaries are completely injected with foam. Long catheters are also used and allow precise deposition of foam throughout the entire vein [168, 169] . In addition, the European Guideline group advised venous puncture of the proximal thigh to treat truncal GSVs in 2012 [167] . Some authors advocate manual compression on the SFJ during UGFS to minimize the flow of foam into the femoral vein [170] . The use of tumescence anesthesia to improve results after UGFS shows no beneficial effect [171] .
The amount of foam required for treatment of GSV insufficiency is usually 6 to 8 mL, depending on length and diameter of the vein [172] . For SSV insufficiency, 4 to 6 mL is sufficient. The total amount of foam should not exceed 10 mL, as higher incidence of side effects are reported with higher volumes of foam [173] .
Optionally, the patient stays in horizontal or reverse Trendelenburg position for 5 minutes after injection of foam to optimize contact between the vein wall and foam. Compression stockings are usually applied for 2 weeks after UGFS [174] . Absolute contraindications for UGFS are severe allergy to sclerosants, acute deep vein thrombosis or pulmonary embolism, local infection in the area of UGFS, and longlasting immobility [167] . In patients with relative contraindications to UGFS (pregnancy, breastfeeding, severe peripheral arterial occlusive disease, high thromboembolic risk, superficial thrombophlebitis), an individual benefit-to-risk assessment should be done [167] . 2 0 1 4 ) 1 1 8 -1 3 6 4.2.
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Mechanisms of action
Sclerotherapy is the use of chemical agents to disrupt the venous wall. Sclerosants act by altering surface tension of endothelial cells [175] . Endothelial damage occurs directly after injection resulting in platelet activation and activation of the coagulation process with thrombus formation [176, 177] . The organization of subendothelial collagen fibers leads to fibrosis and occlusion of the treated vein. Liquid sclerosants are diluted by blood, which reduces the delivered concentration to the vein wall. Foam displaces blood and prolongs direct contact with the endothelium. Therefore, the efficacy of a sclerosant can be increased by foam. Foam is composed of small bubbles of air that are covered with sclerosant. The air inside the foam allows good visibility under ultrasound guidance. Another advantage of foam over liquid sclerotherapy is that a given volume of liquid can be used to produce four times its volume in foam. This allows the use of smaller amounts of sclerosants to achieve a similar effect. Sotradecol is a more potent sclerosant than polidocanol. The mean depth of injury and the percentage of media damage are significantly higher for sotradecol compared with polidocanol [165] . Despite the greater stability of polidocanol over sotradecol, the therapeutic effect of a sclerosant appears to occur in the first seconds after injection [178] . This suggests that the active substance of the sclerosant has more effect than the longevity of contact. Also, higher concentrations of foam sclerosants have greater impact on vein wall injury [179] .
Outcome
Foam, in comparison with liquid sclerotherapy of insufficient saphenous veins, was studied in several randomized trials. A meta-analysis of these studies shows the superiority of foam sclerotherapy. Efficacy of foam was 76.8% versus 39.5% with liquid sclerotherapy [180] . The occlusion rate depends on the diameter of the vein and concentration of injected foam [181] . A large prospective series of 500 patients shows obliteration of the GSV in 81% after 3 years [182] . In addition, 14% of patients required more sessions to obtain these results. The reported occlusion rates of prospective series are listed in Table 3 and vary between 36.1% and 97% [13, 57, 93, 95, 168, 171, 174, . In a randomized controlled trial comparing UGFS versus surgery in 430 patients with insufficient GSVs, anatomical success after 2 years was 65% and 79%, respectively [209] . However, clinical outcomes were similar between both groups. The efficacy of UGFS was inferior to EVLA and RFA in several randomized studies [13, 57] .
Complications
UGFS appears to be a safe method to obliterate varicose veins. A large series of 1,025 patients reported side effects in 2.6% [201] . The incidence of deep venous thrombosis and pulmonary embolism are low. Specific complications for UGFS include visual disturbances, migraine, and, rarely, transient ischemic attack, and are caused by migration of foam. Microembolism in the left heart chamber is observed in 33% to 65% of cases by echocardiography during UGFS [211] . Although microembolism is detected in the cerebral circulation in 14% to 42%, severe complications, such as cerebrovascular accidents are seldom reported [212, 213] . Some patients may develop tightness in the chest or coughing, probably an effect of foam in the lungs [172] . This usually resolves in about 30 minutes. The incidence of hyperpigmentation is up to 33% [214] . Hyperpigmentation is caused by extravasation of red blood cells through the damaged vein wall, but disappears in approximately 70% of patients within 6 months. Compression therapy results in a significant reduction in hyperpigmentation [215] . Severe allergic reaction to the used sclerosant has been described, although this condition is very rare [216] .
5.
Mechanochemical endovenous ablation handle) that controls wire rotation. A 5-mL syringe is attached to the handle and delivers the sclerosant. The center of the catheter is the infusion canal for the liquid sclerosant and contains a rotating wire. At the end of the wire, a small ball is attached to the angled tip, which enhances ultrasound visibility. The wire can be in a sheathed and unsheathed position, whereby 2 cm of the wire extends distal to the catheter tip (Fig. 3) . Under ultrasound guidance, the catheter is inserted via a 4Fr or 5Fr microsheath over a guide wire or 18-gauge cannula and advanced into the GSV. The flexible catheter has a bended tip in sheathed position, which allows navigation through moderate tortuous vein segments. Then, the tip of the wire is placed 0.5 cm below the superior epigastric vein and the rotating wire is unsheathed by connecting the catheter to the handle [217] . Proper positioning of the metal ball below the superior epigastric vein and saphenofemoral valve is essential, and the wire can snag on either the vein wall or valve. Before the infusion of the sclerosant wire rotation is advised for 3 to 10 seconds to create a venospasm in the proximal GSV, followed by continued rotating and pullback with infusion of a sclerosant. The pullback speed is 6 to 7 s/cm [218, 219] . Compression stockings are usually administered for 2 weeks after MOCA.
Sotradecol and polidocanol can both be used as liquid sclerosants. Sclerosant dosage can be obtained from a dosing chart supplied by the company, and depends on vein treatment length and vein diameter. The maximal sclerosant volume depends on the patients' weight when using polidocanol. Instructions for use include treatment with sotradecol 1% for GSV and SSV, and 2% polidocanol for GSV and SSV [217] . When a tributary branch of the GSV is passed during MOCA, pullback can be slowed and/or the infusion rate of the sclerosant can be increased in order to disperse sclerosant into this branch. The collateral distribution of sclerosant into tributaries has a beneficial effect and reduces adjunctive procedures [220] .
Contraindications for MOCA are pre-existent thrombus in the treated vein, use of anticoagulants, and pregnancy. There is no evidence of treating larger GSV (412 mm) with MOCA. Manual compression is advised by the company over the length of the treated vein whenever the vein diameter is 410 mm to enhance mechanical damage to the vein wall.
5.2.
Mechanism of action MOCA combines mechanical damage to the endothelial layer using a rotating wire with the infusion of a liquid sclerosant [221] . The aim of the mechanical damage is to promote coagulation activation by damaging the endothelium; to induce vasospasm, reducing the vein diameter; to increase the action of the sclerosant, and to ensure an even distribution of the sclerosant. The liquid sclerosant then produces irreversible damage to the cellular membranes of the endothelium, resulting in fibrosis of the vein [176] . A histologic study described a complete disappearance of the endothelium and fibrosis of the vein, 1 year after MOCA treatment. Also, considerable damage of the media with collagen changes was observed [222] . In an ex vivo study, the mechanical part of the ClariVein s catheter caused subtle and incomplete destruction of the endothelium without changes to media or adventitia [223] . The additional effect of a sclerosant could lead to the preferred complete endothelial disappearance. However, histopathological studies of MOCA supporting this hypothesis are lacking.
Outcome
In 2009, the first clinical study was performed by Elias and Raines and described 30 limbs treated with sotradecol. Total occlusion of the treated vein segments was seen in 97% at 6 months and 97% at 2 years follow-up [219, 224] . The reported occlusion rates of prospective series are listed in Table 4 and vary between 87% and 97% [218] [219] [220] [224] [225] [226] [227] . The largest series by Bishawi et al reported success in 94% of the 126 patients treated with sotradecol as well as polidocanol [225] . Interestingly, a difference in anatomical success of 87% versus 97% was observed 6 months after MOCA between patients treated with polidocanol 1.5% and 2% [226] . In this observational study, 50 patients with insufficient SSVs were included. A randomized study comparing MOCA with RFA reported similar occlusion rates of 92% after 4 weeks [227] .
Complications
Because no heat is generated with MOCA, heat-related complications, such as skin burn and paresthesia, will not appear. MOCA is associated with less postprocedural pain compared to RFA in the first 14 days after treatment, which also results in a faster recovery [227, 228] . Other possible complications are comparable with other endovenous techniques. Deep venous thrombosis and pulmonary embolism have not been described after MOCA, but are potential complications after all endovenous procedures. Superficial thrombophlebitis occurs in 12% to 14%, which is comparable to UGFS [220, 226] .
Endovenous steam ablation
Technique
Endovenous steam ablation (EVSA) is an endovenous technique that uses steam to heat the vein. EVSA can be performed in an outpatient setting with tumescence anesthesia. Venous access is obtained by a 16-or 19-gauge cannula or 5Fr microintroducer set under ultrasound guidance. The steam ablation catheter is advanced into the GSV and positioned 2 to 3 cm below the SFJ [105, 229] . As with other techniques, proper positioning of the echogenic tip of the catheter is the most essential step during the treatment. Application of tumescence anesthesia is similar to EVLA and RFA, and decreases the venous diameter. In a special generator, pressurized sterile water is injected into a microtube that is heated by electrical current. The heated water is emitted at the tip of a hand piece as pulses of steam at 1501C. A catheter is connected to the steam-emitting hand piece and carries the steam into the vein through two lateral holes near the tip (Fig. 4) . At the tip of the catheter, the temperature decreases to 1201C. After activation, two pulses of steam are delivered to dispel the condensated water from the catheter. Then, three pulses are released at the tip of the 
catheter to treat the most proximal GSV. The catheter is pulled down stepwise for segments of 1 cm, applying 2 to 4 pulsed steam puffs/cm. The number of pulses depends on the vein diameter [105] . The same generator also allows the ability to obliterate tributaries with a special designed catheter. After the procedure, compression stockings are usually advised for 1 to 2 weeks. Relative contraindications for EVSA are comparable to EVLA and include thrombus in the vein segment to be treated, immobility, severe arterial disease, deep vein thrombosis, pregnancy, and patients who are breastfeeding.
6.2.
Mechanism of action EVSA utilizes the condensation of steam into water, which releases lots of energy in a short time and produces a thermal effect on the vein wall. The steam condensates back to water and the resulting heat is absorbed by the vein wall. One pulse has a heating capacity of 60 J. Because the temperature of steam is delivered in a regulated temperature of 1201C, the mechanisms of action are very similar to RFA. In vitro temperature measurements of EVSA showed a longer plateau phase of heat and lower maximum temperature than EVLA, which was comparable to RFA [230] . In addition, temperature significantly rises inside the vein when more pulses of steam are delivered.
In an animal study, disappearance of the endothelium was observed immediately after EVSA. This process was followed by fibrotic thrombosis, inflammatory reaction of the media, and eventually fibrosis of the treated vein [229, 231] .
Outcome
The first results of EVSA were published by Van den Bos et al [229] in 2011. Twenty limbs were treated with total occlusion of 65% at 6 months. The reported recanalization only affected segments o10 cm of the treated GSV. In a multicenter study treating 88 veins with GSV insufficiency, success was 96.1% after 1-year follow-up [232] . The reported occlusion rates in prospective series are listed in Table 5 and vary between 65% and 96% [105, 229, 232, 233] . A randomized controlled study comparing EVSA with RFA showed the inferiority of EVSA, with success rates of 87% versus 96% after 1 year [105] . However, patients treated with high-dose EVSA reported similar results compared with EVLA.
Complications
Possible complications of EVSA are comparable with those of EVLA and RFA. Paresthesia is observed in 2% after EVSA [105] . No deep venous thrombosis or pulmonary embolism has been reported. However, extension of the thrombus for 1 cm in the deep femoral vein was observed, which disappeared after low-molecular-weight heparin treatment [234] . EVSA is associated with significant lower postprocedural pain than EVLA [105] . . 2 0 1 4 ) 1 1 8 -1 3 6 7.
Discussion
The treatment of varicose veins has changed dramatically over the past years. Although high saphenous ligation with surgical stripping has been the gold standard during most of the 20 th century, endovenous techniques have replaced traditional surgery as a result of similar efficacy, faster recovery, less postprocedural complications, and improved quality of life [15] . Since the introduction of endovenous techniques, many prospective series and randomized studies have been published on the efficacy of treatment. Unfortunately, most studies are focused on technical feasibility and short-term outcomes, while evidence of long-term outcomes is thriftily.
Only a few studies have reported occlusion rates more than 5 years after endovenous procedures [86, 87, 96, 127, 182, 183, 198] . Long-term results of randomized controlled studies are needed to provide an answer on the durability of endovenous techniques, especially for newer techniques, such as MOCA and EVSA.
Results of a recent meta-analysis and systematic Cochrane review suggest that efficacy of EVLA, RFA, and UGFS is nonsignificantly different compared with surgery [15, 235] . However, heterogeneity in the definition of "efficacy" or "success" is a major problem in comparing results between techniques. Success and efficacy are often revealed as the absence of recanalization, which varies from "no evidence of flow in the treated vein" to "flow in segments less than 15% of the total treated segment." Therefore, standardization of outcome parameters after varicose vein ablation is necessary to optimize comparison in the future [236] .
The most pivotal outcome of varicose vein treatment should be the clinical outcome that is most important to patients. Clinical outcomes that are significant for patients include the relief of symptoms, improvement in quality of life, prevention of ulceration, and satisfaction with aesthetics. Deterioration of these patient-specific outcomes is normally clinical expression of recurrence. However, ultrasoundproven occlusion rates are usually used as substitute for clinical recurrence, that disregards other causes of recurrence, such as neovascularization, reflux in the GSV below the knee and tributaries [237] .
Several advantages and disadvantages can be summarized from the current literature. EVLA and RFA report high occlusion rates, and UGFS often needs multiple treatments to achieve the same results. Mid-term efficacy of newer endovenous techniques, like MOCA and EVSA, are not yet defined. All endovenous techniques are performed in outpatient setting. Major complications are rare and comparable between procedures [238] . Postprocedural pain is related to the amount of heat that is released during treatment. RFA, UGFS, and EVSA have reported less postprocedural pain compared to EVLA [13, 105, 112] . MOCA is associated with significantly less postprocedural pain than RFA [228] . An advantage of UGFS and MOCA over endothermal techniques is the omission of tumescence anesthesia, which is time consuming and needs multiple injections.
Some considerations should be given to the costeffectiveness of endovenous procedures, while reimbursement for the treatment of varicose veins is not guaranteed in several countries. Procedural costs of UGFS are lower than with EVLA and RFA, due to the use of disposable catheters and a generator [13] . However, costs of treatment failures, adjunctive procedures of tributaries, and speed of recovery are also important parameters influencing cost-effectiveness. In a systematic review, differences between these parameters were negligible and cost-effectiveness is therefore associated with long-term clinical success of the treatment [239] .
This literature review aimed to describe the current performance of endovenous techniques in the treatment of varicose veins. As a consequence of their potential advantages in patient's comfort and low incidence of complications, several evolutions are made in nonthermal ablation. r e f e r e n c e s
